Neurofilament light chain levels in serum among a large mixed memory clinic cohort: Confounders and diagnostic usefulness

Early and accurate diagnosis of neurocognitive disorders including neurodegenerative dementia remains challenging. This study explores the impact of biological factors on serum neurofilament light chain (NfL) levels and clinical usefulness for the detection of neurocognitive disorders in a mixed memory clinic.

[1]  Irina Madorsky,et al.  Uman-type neurofilament light antibodies are effective reagents for the imaging of neurodegeneration , 2023, Brain communications.

[2]  K. Blennow,et al.  Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer’s disease and frontotemporal lobar degeneration , 2022, Alzheimer's Research & Therapy.

[3]  R. Frikke-Schmidt,et al.  Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease , 2022, International journal of molecular sciences.

[4]  M. Carrillo,et al.  The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[5]  K. Blennow,et al.  Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years , 2022, Brain communications.

[6]  P. Calabresi,et al.  Contributors to Serum NfL Levels in People without Neurologic Disease , 2022, Annals of neurology.

[7]  W. M. van der Flier,et al.  Global estimates on the number of persons across the Alzheimer's disease continuum , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[8]  D. Conen,et al.  Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study , 2022, The Lancet Neurology.

[9]  W. M. van der Flier,et al.  Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia , 2022, Alzheimer's & dementia.

[10]  W. Flier,et al.  Blood-based biomarkers for Alzheimer's disease: towards clinical implementation , 2021, The Lancet Neurology.

[11]  P. Svenningsson,et al.  A multicentre validation study of the diagnostic value of plasma neurofilament light , 2021, Nature Communications.

[12]  A. Winston,et al.  Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis , 2021, BMJ Neurology Open.

[13]  P. O’Reilly,et al.  Causal Associations Between Modifiable Risk Factors and the Alzheimer's Phenome , 2020, Annals of neurology.

[14]  P. Matthews,et al.  Neurofilaments: neurobiological foundations for biomarker applications. , 2020, Brain : a journal of neurology.

[15]  T. Hortobágyi,et al.  An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders , 2020, Nature Reviews Neurology.

[16]  G. Waldemar,et al.  Validation of the Brief Assessment of Impaired Cognition and the Brief Assessment of Impaired Cognition Questionnaire for identification of mild cognitive impairment in a memory clinic setting , 2020, International journal of geriatric psychiatry.

[17]  T. Parkner,et al.  Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults , 2020, Scandinavian journal of clinical and laboratory investigation.

[18]  K. Blennow,et al.  Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. , 2019, JAMA neurology.

[19]  J. Sussman,et al.  Serum NfL (Neurofilament Light Chain) Levels and Incident Stroke in Adults With Diabetes Mellitus. , 2019, Stroke.

[20]  P. Calabresi,et al.  Neurofilament light chain as a biomarker in neurological disorders , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[21]  Ludwig Kappos,et al.  Neurofilaments as biomarkers in neurological disorders , 2018, Nature Reviews Neurology.

[22]  A. Rule,et al.  Structural and Functional Changes in Human Kidneys with Healthy Aging. , 2017, Journal of the American Society of Nephrology.

[23]  F. Elahi,et al.  A clinicopathological approach to the diagnosis of dementia , 2017, Nature Reviews Neurology.

[24]  Alan J. Thomas,et al.  Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.

[25]  Murray Grossman,et al.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria , 2017, Movement disorders : official journal of the Movement Disorder Society.

[26]  Veeranna,et al.  Neurofilaments and Neurofilament Proteins in Health and Disease. , 2017, Cold Spring Harbor perspectives in biology.

[27]  K. Blennow,et al.  Blood-based NfL , 2017, Neurology.

[28]  Henrik Zetterberg,et al.  Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.

[29]  K. Jellinger,et al.  Diagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement , 2014, Alzheimer disease and associated disorders.

[30]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[31]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[32]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[33]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[34]  E. Tolosa,et al.  Clinical diagnostic criteria for dementia associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[35]  Marvin Bergsneider,et al.  Diagnosing Idiopathic Normal-pressure Hydrocephalus , 2005, Neurosurgery.

[36]  A. Alavi,et al.  MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. , 1987, AJR. American journal of roentgenology.